Last update 08 May 2025

ALPPL2 x CD3

Basic Info

Related Targets
ALPPL2CD3

Related

1
Drugs associated with ALPPL2 x CD3
ATG-112
Target
ALPPL2 x CD3
Mechanism
ALPPL2 inhibitors [+1]
Active Org.
Antengene Corp. Ltd.Antengene Corp. Ltd.
Originator Org.
Antengene Corp. Ltd.Antengene Corp. Ltd.
Active Indication
Solid tumor
Inactive Indication-
Drug Highest PhasePreclinical
First Approval Ctry. / Loc.-
First Approval Date20 Jan 1800
100 Clinical Results associated with ALPPL2 x CD3
Login to view more data
100 Translational Medicine associated with ALPPL2 x CD3
Login to view more data
0 Patents (Medical) associated with ALPPL2 x CD3
Login to view more data
1
Literatures (Medical) associated with ALPPL2 x CD3
01 May 2025Biochemical and Biophysical Research Communications
Targeting ALPPL2 with a novel CD89 bispecific antibody reprograms macrophages to enhance anti-tumor immunity

Analysis

Perform a panoramic analysis of this field.
login
or
view full example data
Perform a panoramic analysis of this field.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free